Summary

The global hospital infection therapeutics market size reached US$ 12.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.9 Billion by 2032, exhibiting a growth rate (CAGR) of 4.55% during 2024-2032. The escalating incidence of multidrug-resistant infections, a growing emphasis on antimicrobial stewardship, continuous advancements in research and development (R&D), and increased healthcare expenditure and infrastructure development worldwide represent some of the key factors influencing the market growth.

Hospital Infection Therapeutics Market Analysis:
• Market Growth and Size: The global hospital infection therapeutics market is experiencing robust growth, driven by an increasing incidence of hospital-acquired infections and the demand for effective treatment solutions. The market size is expanding steadily, fueled by rising healthcare expenditure and infrastructure development worldwide.
• Major Market Drivers: Key drivers include the prevalence of multidrug-resistant infections, growing awareness of antimicrobial stewardship programs, continuous advancements in R&D, and a rise in healthcare expenditure globally.
• Technological Advancements: Ongoing technological advancements, particularly in genomics, microbiology, and immunology, are contributing to the discovery of novel drug targets and the development of advanced hospital infection therapeutics, such as monoclonal antibodies and combination therapies.
• Industry Applications: Hospital infection therapeutics are applied across various indications, including bloodstream infections, urinary tract infections (UTI), surgical site infections, pneumonia, and others, addressing specific challenges associated with each category.
• Key Market Trends: The rising focus on antimicrobial stewardship, increasing research collaborations, mergers and acquisitions to expand product portfolios, and the development of alternative therapeutics beyond traditional categories are some of the emerging trends strengthening the market growth.
• Geographical Trends: Geographically, North America and Europe lead in demand, driven by robust healthcare infrastructures and stringent regulatory frameworks. While Asia Pacific is witnessing significant growth due to increased healthcare investments and infrastructure development.
• Competitive Landscape: The competitive landscape is intense, with pharmaceutical companies engaged in R&D, strategic collaborations, and mergers and acquisitions. The emphasis on aligning products with antimicrobial stewardship principles shapes industry strategies.
• Challenges and Opportunities: The emergence of drug-resistant strains is creating challenges for market development, while opportunities lie in addressing specific indications within the hospital infection spectrum and leveraging technological innovations for therapeutic development.
Hospital Infection Therapeutics Market Trends:
Increasing incidence of hospital-acquired infections (HAIs):
One of the primary drivers of the hospital infection therapeutics market is the rising incidence of HAIs. These infections can be bacterial, viral, or fungal in nature and are often associated with invasive medical procedures, surgeries, or the use of medical devices. The prevalence of HAIs is a major concern globally, leading to an increased demand for effective therapeutics to manage and treat these infections. Besides this, the spread of drug-resistant pathogens within healthcare settings has further intensified the need for advanced and targeted treatment options, necessitating the development of innovative and potent therapeutics to combat these infections effectively.
Growing awareness of antimicrobial stewardship programs
Antimicrobial stewardship programs have gained prominence as a key strategy to combat the emergence and spread of antimicrobial resistance. These programs focus on optimizing the use of antimicrobial agents to improve patient outcomes while minimizing the development of resistance. The growing awareness of antimicrobial stewardship has led to an increased emphasis on the development and adoption of novel therapeutics that can address the specific challenges posed by drug-resistant pathogens, creating a positive outlook for market expansion. Moreover, various healthcare organizations and regulatory bodies across the globe are actively promoting antimicrobial stewardship to ensure the judicious use of antibiotics and other antimicrobial agents are providing an impetus to the market growth.
Significant advancements in R&D activities
Ongoing R&D activities in the field of infectious diseases have contributed significantly to the expansion of the hospital infection therapeutics market. In line with this, advancements in genomics, microbiology, and immunology have provided valuable insights into the mechanisms of infection and the identification of novel drug targets. The discovery of new antimicrobial compounds and the development of combination therapies are aiding in market expansion. In addition to this, extensive collaborations between pharmaceutical companies, academic institutions, and research organizations have propelled the discovery and development of innovative therapeutic modalities, including monoclonal antibodies, vaccines, and novel antibiotics, thereby impelling the market growth.
Rising healthcare expenditure and infrastructure development
The global increase in healthcare expenditure and ongoing infrastructure development in the healthcare sector are fueling the growth of the hospital infection therapeutics market. Concurrent with this, numerous governments and private investors are investing in the expansion and modernization of healthcare facilities, including hospitals and clinics. This, in turn, drives the demand for infection therapeutics to equip healthcare providers with effective tools to manage and control the incidence of HAIs, thus bolstering the market growth. Furthermore, the expansion of healthcare infrastructure in emerging economies has opened up new markets for hospital infection therapeutics. As healthcare access improves, there is a surging demand for advanced treatment options to address the healthcare challenges associated with infectious diseases.
Hospital Infection Therapeutics Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on drug type and indication.
Breakup by Drug Type:
• Anti-bacterial Drugs
• Anti-fungal Drugs
• Anti-viral Drugs
• Others

Anti-bacterial drugs accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the drug type. This includes anti-bacterial, anti-fungal, anti-viral, and other drugs. According to the report, anti-bacterial drugs represented the largest segment.
The rising demand for anti-bacterial hospital infection therapeutics driven by the escalating threat of multidrug-resistant bacteria, necessitating the development of effective antibiotics to combat evolving bacterial strains is fostering market expansion.
In confluence with this, the increasing prevalence of invasive fungal infections, particularly in immunocompromised patients, is propelling the demand for anti-fungal drugs, addressing the unique challenges posed by fungal hospital-acquired infections.
Additionally, the expanding demand for targeted anti-viral hospital infection therapeutics due to the persistent threat of viral outbreaks, such as influenza and emerging viruses is acting as another significant growth-inducing factor.
Diverse infectious agents and evolving resistance patterns spurring the demand for innovative therapeutics beyond conventional categories and leading to the development of alternative drugs to address specific hospital infection challenges are presenting lucrative opportunities for market expansion.
Breakup by Indication:
• Blood Stream Infections
• Urinary Tract Infections
• Surgical Site Infections
• Pneumonia
• Others

Surgical site infections holds the largest share of the industry
A detailed breakup and analysis of the market based on the indication have also been provided in the report. These include blood stream infections, urinary tract infections, surgical site infections, pneumonia, and others. According to the report, surgical site infections accounted for the largest market share.
The escalating concerns about surgical site infections due to the risk they pose to postoperative recovery are bolstering the need for specialized drugs to prevent and manage infections at surgical sites, thereby propelling the market forward.
The critical nature of blood stream infections, necessitating effective treatments to prevent systemic complications and improve patient outcomes is contributing to the increasing demand and sales of hospital infection therapeutics.
Concurrently, the rising incidences of urinary tract infections (UTIs) are further boosting the demand for therapeutics, with a focus on addressing the specific challenges associated with UTIs, including recurrent infections and antibiotic resistance.
Moreover, the increasing complexity associated with respiratory infections like pneumonia is also fostering the demand for effective hospital infection therapeutics to combat bacterial, viral, and fungal pneumonia, ensuring optimal patient care.
Apart from this, growing cases of skin and soft tissue infections, gastrointestinal infections, and respiratory tract infections driving the demand for specialized hospital infection therapeutics are influencing market expansion.
Breakup by Region:
• North America
o United States
o Canada
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Others
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Russia
o Others
• Latin America
o Brazil
o Mexico
o Others
• Middle East and Africa

Europe leads the market, accounting for the largest hospital infection therapeutics market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe accounted for the largest market share.
The rising awareness of infectious diseases, well-established healthcare systems, and a proactive approach to antimicrobial stewardship in Europe leading to a continuous need for advanced therapeutics are contributing to the market expansion.
Moreover, North America’s robust healthcare infrastructure, stringent regulatory frameworks, and a high prevalence of healthcare-associated infections necessitating effective treatment solutions are positively impacting the market growth.
Furthermore, extensive healthcare investments, a growing burden of infectious diseases, and a surge in hospital infrastructure development in the Asia Pacific are creating remunerative opportunities for the expansion of the hospital infection therapeutics market.
Besides this, Latin America’s evolving healthcare policies and supportive efforts aimed at enhancing healthcare accessibility while expanding healthcare infrastructure and a rising focus on healthcare quality in the Middle East and Africa emphasizing the need for advanced hospital infection therapeutics are propelling the market growth.
Leading Key Players in the Hospital Infection Therapeutics Industry:
The global hospital infection therapeutics market is characterized by intense competition among pharmaceutical companies striving to address the increasing prevalence of hospital-acquired infections. Key players in the market are engaged in extensive R&D activities to introduce innovative therapeutics, ranging from antibiotics to antiviral drugs, tailored to combat multidrug-resistant pathogens. Strategic collaborations and partnerships between industry players, academic institutions, and research organizations are commonplace, fostering the exchange of knowledge and expertise. The emphasis on antimicrobial stewardship programs further shapes the competitive landscape, with companies working to align their products with principles promoting the judicious use of antimicrobial agents. Regulatory compliance, market penetration strategies, and a focus on addressing specific indications within the hospital infection spectrum are pivotal factors influencing the competitive dynamics of this dynamic and evolving market.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
• Allergan Plc (AbbVie Inc.)
• AstraZeneca Plc
• Bayer Aktiengesellschaft
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG (Roche Holding AG)
• Gilead Sciences Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co. Inc
• Pfizer Inc.
• Sanofi S.A.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
Latest News:
• In December 2023, F. Hoffmann-La Roche AG (Roche Holding AG) entered into a definitive merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately owned US company based in Berkeley, California.
• In October 2023, Gilead announced its collaboration with Assembly Biosciences to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio’s established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D virus (HDV).
• In March 2023, GSK plc and SCYNEXIS, Inc. announced that they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA-approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and reduction in the incidence of recurrent VVC (RVVC).

Key Questions Answered in This Report:
• How has the global hospital infection therapeutics market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global hospital infection therapeutics market?
• What is the impact of each driver, restraint, and opportunity on the global hospital infection therapeutics market?
• What are the key regional markets?
• Which countries represent the most attractive hospital infection therapeutics market?
• What is the breakup of the market based on the drug type?
• Which is the most attractive drug type in the hospital infection therapeutics market?
• What is the breakup of the market based on the indication?
• Which is the most attractive indication in the hospital infection therapeutics market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global hospital infection therapeutics market?

ページTOPに戻る

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Hospital Infection Therapeutics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Type
6.1 Anti-bacterial Drugs
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Anti-fungal Drugs
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Anti-viral Drugs
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Indication
7.1 Blood Stream Infections
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Urinary Tract Infections
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Surgical Site Infections
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Pneumonia
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Allergan Plc (AbbVie Inc.)
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 AstraZeneca Plc
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 Bayer Aktiengesellschaft
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.3.4 SWOT Analysis
13.3.4 Bristol-Myers Squibb Company
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 SWOT Analysis
13.3.6 Gilead Sciences Inc.
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 GlaxoSmithKline Plc
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 Johnson & Johnson
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.8.4 SWOT Analysis
13.3.9 Merck & Co. Inc.
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.9.4 SWOT Analysis
13.3.10 Pfizer Inc.
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.10.3 Financials
13.3.10.4 SWOT Analysis
13.3.11 Sanofi S.A.
13.3.11.1 Company Overview
13.3.11.2 Product Portfolio
13.3.11.3 Financials
13.3.11.4 SWOT Analysis
List of Figures
Figure 1: Global: Hospital Infection Therapeutics Market: Major Drivers and Challenges
Figure 2: Global: Hospital Infection Therapeutics Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Hospital Infection Therapeutics Market: Breakup by Drug Type (in %), 2023
Figure 4: Global: Hospital Infection Therapeutics Market: Breakup by Indication (in %), 2023
Figure 5: Global: Hospital Infection Therapeutics Market: Breakup by Region (in %), 2023
Figure 6: Global: Hospital Infection Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 7: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 8: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 9: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 10: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 11: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: Global: Hospital Infection Therapeutics (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: Global: Hospital Infection Therapeutics (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: Global: Hospital Infection Therapeutics (Pneumonia) Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: Global: Hospital Infection Therapeutics (Pneumonia) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: Global: Hospital Infection Therapeutics (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: Global: Hospital Infection Therapeutics (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: North America: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: North America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: United States: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 28: United States: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 29: Canada: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 30: Canada: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 31: Asia Pacific: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 32: Asia Pacific: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 33: China: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 34: China: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 35: Japan: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 36: Japan: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 37: India: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 38: India: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 39: South Korea: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 40: South Korea: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 41: Australia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 42: Australia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 43: Indonesia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 44: Indonesia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 45: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 46: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 47: Europe: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 48: Europe: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 49: Germany: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 50: Germany: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 51: France: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 52: France: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 53: United Kingdom: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 54: United Kingdom: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 55: Italy: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 56: Italy: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 57: Spain: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 58: Spain: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 59: Russia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 60: Russia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 61: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 62: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 63: Latin America: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 64: Latin America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 65: Brazil: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 66: Brazil: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 67: Mexico: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 68: Mexico: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 69: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 70: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 71: Middle East and Africa: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 72: Middle East and Africa: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 73: Global: Hospital Infection Therapeutics Industry: SWOT Analysis
Figure 74: Global: Hospital Infection Therapeutics Industry: Value Chain Analysis
Figure 75: Global: Hospital Infection Therapeutics Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: Global: Hospital Infection Therapeutics Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
Table 3: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Indication (in Million US$), 2024-2032
Table 4: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 5: Global: Hospital Infection Therapeutics Market Structure
Table 6: Global: Hospital Infection Therapeutics Market: Key Players